ClinicalTrials.gg
CompletedNCT06996886Updated Jul 31, 2025

A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations

A Phase 1 interventional study of AZD5004 in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.

Enrollment
17th of 18
16 · median 57
Started
2025
with 2 others
Phase 1
11 of 18
none open now
Registered
9th of 18
by date
Lead sponsor
14 of 18
AstraZeneca

Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 17th largest by enrollment, is one of 3 that started in 2025, is one of 11 in phase 1, and was the 9th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About elecoglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to assess the relative bioavailability of a single dose AZD5004 in healthy participants, among 3 different oral tablet formulations.

Read the detailed description

This study will be an open-label, randomized, 4-period, 4-treatment, single-dose crossover study in healthy participants.

Participants will receive one single dose of AZD5004 at the beginning of each of the four Treatment Periods, and a total of 4 doses of AZD5004. Three different formulations (F1, F3, and F4) will be used across the Treatment Periods.

The study comprises of total four treatment periods.

  • A Screening Period of maximum 27 days. Four Treatment Periods of 7 days each.
  • Treatment Period 1 (Day -1 to Day 6)
  • Treatment Period 2 (Day 7 to Day 13)
  • Treatment Period 3 (Day 14 to Day 20)
  • Treatment Period 4 (Day 21 to Day 27)
  • A final Follow-up Visit within 7 to 10 days after the last study intervention administration (Day 22 of Treatment Period 4).

The treatments are as follows:

  • Treatment 1: Single dose of AZD5004 in Formulation 1 (F1) -fasted
  • Treatment 2: Single dose of AZD5004 in Formulation 4 (F4) -fasted
  • Treatment 3: Single dose of AZD5004 in F4- fed
  • Treatment 4: Single dose of AZD5004 in Formulation 3 (F3) - fasted

Participants will be randomized equally to one of the following treatment sequences:

  • Treatment Sequence A: F1, F4, F4 (fed), F3
  • Treatment Sequence B: F4, F4 (fed), F3, F1
  • Treatment Sequence C: F4 (fed), F3, F1, F4
  • Treatment Sequence D: F3, F1, F4, F4 (fed)
03

Conditions studied

  • Healthy Participants

Keywords

  • Relative bioavailability
  • GLP-1 receptor agonist
  • Type 2 Diabetes Mellitus
  • Obesity
  • Oral tablet formulations
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • Healthy male and female participants with suitable veins for cannulation or repeated venipuncture.
  • Female participants:

    1. Female(s) of : If heterosexually active must agree to use an approved method of highly effective .
    2. Female(s) not of childbearing potential
  • Male participants:

    1. Condom use is required for the duration of the clinical study.
    2. Additional contraception must be used for the sexual partners of male study participants throughout the clinical study.
  • Have a (BMI) ≥ 23 kg/m2 and not exceeding 35 kg/m2 inclusive (at the time of Screening) and weigh at least 60 kg.

Main Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study
  • History of acute pancreatitis (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy), chronic pancreatitis, gallstones, or elevation in serum lipase/pancreatic amylase.
  • Clinically significant inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper GI tract (including bariatric surgery).
  • Any clinically important illness, medical/surgical procedure, or trauma.
  • Any laboratory values with the deviations specified in protocol and clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.
  • Any positive result at Screening for serum surface antigen (HBsAg), Hepatitis B core antibody (HBcAb) or (HIV).
  • Abnormal vital signs, after 10 minutes supine rest, at Screening and/or admission to the Clinical Unit.
  • Serum triglyceride concentrations above 1000 mg/dL (11 mmol/L).
  • Basal calcitonin level > 50 ng/L or pg/mL at Screening or history/family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia (MEN), type 2.
  • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol
  • Positive screen for drugs of abuse, or alcohol or cotinine (nicotine).
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity or history of hypersensitivity to drugs with a similar chemical structure or class to AZD5004.
  • Excessive intake of caffeine-containing drinks or food
  • History of psychosis or bipolar disorder and major depressive disorder.
  • History of suicide attempt or history of suicidal ideation within the past year.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Treatment Sequence A

    Participants will receive single dose of AZD5004 on Day 1 in F1 (fasted) (Treatment period 1), on Day 8 in F4 (fasted) (Treatment period 2), on Day 15 in F4(fed) (Treatment Period 3) followed by on Day 22 in F3 (fasted) (Treatment Period 4) respectively.

    Drug: AZD5004

  • Experimental
    Treatment Sequence B

    Partcipants will receive single dose of AZD5004 on Day 1 in F4 (fasted) (Treatment Period 1), on Day 8 in F4 (fed) (Treatment Period 2), on Day 15 in F3 (fasted) (Treatment Period 3) followed by on Day 22 in F1 (fasted) (Treatment Period 4) respectively.

    Drug: AZD5004

  • Experimental
    Treatment Sequence C

    Participants will receive single dose of AZD5004 on Day 1 in F4 (fed) (Treatment Period 1), on Day 8 in F3 (fasted) (Treatment Period 2, on Day 15 in F1 (fasted) (Treatment Period 3 followed by on Day 22 in F4 (fasted) (Treatment Period 4) respectively.

    Drug: AZD5004

  • Experimental
    Treatment Sequence D

    Participants will receive single dose of AZD5004 on Day 1 in F3 (fasted) (Treatment Period 1), Day 8 in F1 (fasted) (Treatment Period 2), on Day 15 in F4 (fasted) (Treatment Period 3) followed by Day 22 in F4 (fed) (Treatment Period 4) respectively.

    Drug: AZD5004

Interventions

  • Participants will be receiving three different formulations (F1, F3, and F4) as single dose of AZD5004 orally in fasted and fed state.

06

What researchers measure

Primary outcomes

  1. Area under concentration-time curve from time 0 to infinity (AUCinf)

    To assess the relative bioavailability of AZD5004 in 3 different solid oral formulations (F1, F3, F4)

    Time frame: Day 1-6, Day 8-13, Day 15-20 and Day 22-27

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To assess the relative bioavailability of AZD5004 in 3 different solid oral formulations (F1, F3, F4)

    Time frame: Day 1-6, Day 8-13, Day 15-20 and Day 22-27

  3. Maximum observed drug concentration (Cmax)

    To assess the relative bioavailability of AZD5004 in 3 different solid oral formulations (F1, F3, F4)

    Time frame: Day 1-6, Day 8-13, Day 15-20 and Day 22-27

  4. Time to reach maximum observed concentration (tmax)

    To assess the relative bioavailability of AZD5004 in 3 different solid oral formulations (F1, F3, F4)

    Time frame: Day 1-6, Day 8-13, Day 15-20 and Day 22-27

  5. Half-life (t½)

    To assess the relative bioavailability of AZD5004 in 3 different solid oral formulations (F1, F3, F4)

    Time frame: Day 1-6, Day 8-13, Day 15-20 and Day 22-27

  6. Apparent total body clearance (CL/F)

    To assess the relative bioavailability of AZD5004 in 3 different solid oral formulations (F1, F3, F4)

    Time frame: Day 1-6, Day 8-13, Day 15-20 and Day 22-27

Secondary outcomes

  1. Area under concentration-time curve from time 0 to infinity (AUCinf)

    To assess the food effect on the relative bioavailability of AZD5004 in one solid oral formulation (F4)

    Time frame: Day 1-6, Day 8-13, Day 15-20 and Day 22-27

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To assess the food effect on the relative bioavailability of AZD5004 in one solid oral formulation (F4)

    Time frame: Day 1-6, Day 8-13, Day 15-20 and Day 22-27

  3. Maximum observed drug concentration (Cmax)

    To assess the food effect on the relative bioavailability of AZD5004 in one solid oral formulation (F4)

    Time frame: Day 1-6, Day 8-13, Day 15-20 and Day 22-27

  4. Time to reach maximum observed concentration (tmax)

    To assess the food effect on the relative bioavailability of AZD5004 in one solid oral formulation (F4)

    Time frame: Day 1-6, Day 8-13, Day 15-20 and Day 22-27

  5. Half-life (t½)

    To assess the food effect on the relative bioavailability of AZD5004 in one solid oral formulation (F4)

    Time frame: Day 1-6, Day 8-13, Day 15-20 and Day 22-27

  6. Apparent total body clearance (CL/F)

    To assess the food effect on the relative bioavailability of AZD5004 in one solid oral formulation (F4)

    Time frame: Day 1-6, Day 8-13, Day 15-20 and Day 22-27

  7. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    To study the safety and tolerability of a single dose AZD5004 in 3 different solid oral formulations (F1, F3, F4), and F4 under fasted and fed conditions in healthy participants

    Time frame: Screening (Day -28 to Day -2) up to Follow-up (Day 29 to Day 32)

07

Study locations

1 site
  • Research Site
    Baltimore, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jul 2025, 1 month.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
May 30, 2025
StartActual
May 22, 2025
Primary completionActual
Jul 15, 2025
CompletionActual
Jul 25, 2025
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06996886
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
May 30, 2025
Start date
May 22, 2025
Primary completion
Jul 15, 2025
Completion
Jul 25, 2025
Last update
Jul 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion